Insider Transactions in Q1 2024 at Biomarin Pharmaceutical Inc (BMRN)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 28
2024
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
24,602
-30.58%
|
$2,164,976
$88.34 P/Share
|
|
Mar 18
2024
|
Dennis Slamon Director |
SELL
Payment of exercise price or tax liability
|
Direct |
9,510
-23.3%
|
$789,330
$83.81 P/Share
|
|
Mar 18
2024
|
Dennis Slamon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+19.68%
|
$790,000
$79.7 P/Share
|
|
Mar 18
2024
|
Erin Burkhart GVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
372
-1.98%
|
$30,876
$83.87 P/Share
|
|
Mar 15
2024
|
Erin Burkhart GVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,720
+20.06%
|
-
|
|
Mar 15
2024
|
Charles Greg Guyer EVP, Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
20,424
-20.68%
|
$1,695,192
$83.87 P/Share
|
|
Mar 15
2024
|
Charles Greg Guyer EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,550
+9.65%
|
-
|
|
Mar 15
2024
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
21,699
-21.24%
|
$1,801,017
$83.87 P/Share
|
|
Mar 15
2024
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,260
+9.13%
|
-
|
|
Mar 15
2024
|
Henry J Fuchs President, Worldwide R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
33,485
-14.54%
|
$2,779,255
$83.87 P/Share
|
|
Mar 15
2024
|
Henry J Fuchs President, Worldwide R&D |
BUY
Grant, award, or other acquisition
|
Direct |
18,240
+7.34%
|
-
|
|
Mar 15
2024
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
20,789
-22.44%
|
$1,725,487
$83.87 P/Share
|
|
Mar 15
2024
|
Brian Mueller EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,400
+10.96%
|
-
|
|
Mar 15
2024
|
Jean Jacques Bienaime Director |
SELL
Payment of exercise price or tax liability
|
Direct |
85,209
-15.21%
|
$7,072,347
$83.87 P/Share
|
|
Mar 15
2024
|
Alexander Hardy Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,780
+18.12%
|
-
|
|
Mar 15
2024
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
22,580
-24.01%
|
$1,874,140
$83.87 P/Share
|
|
Mar 06
2024
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
1,000
-0.18%
|
$86,000
$86.71 P/Share
|
|
Mar 05
2024
|
Henry J Fuchs President, Worldwide R&D |
SELL
Open market or private sale
|
Direct |
35,341
-14.28%
|
$3,003,985
$85.18 P/Share
|
|
Mar 05
2024
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
1,000
-0.18%
|
$85,000
$85.51 P/Share
|
|
Mar 05
2024
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,000
-4.08%
|
$348,000
$87.07 P/Share
|
|
Feb 27
2024
|
Brian Mueller EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,125
+13.61%
|
-
|
|
Feb 27
2024
|
Charles Greg Guyer EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,187
+12.95%
|
-
|
|
Feb 27
2024
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,187
+12.46%
|
-
|
|
Feb 27
2024
|
Henry J Fuchs President, Worldwide R&D |
BUY
Grant, award, or other acquisition
|
Direct |
53,204
+6.96%
|
-
|
|
Feb 27
2024
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,243
+12.04%
|
-
|
|
Feb 27
2024
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
1,000
-0.18%
|
$90,000
$90.35 P/Share
|
|
Feb 27
2024
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
143,601
+8.21%
|
-
|
|
Feb 09
2024
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
15,000
-3.45%
|
$1,320,000
$88.28 P/Share
|
|
Feb 09
2024
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+3.34%
|
$945,000
$63.1 P/Share
|
|
Feb 08
2024
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
15,000
-3.45%
|
$1,335,000
$89.77 P/Share
|
|
Feb 08
2024
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+3.34%
|
$945,000
$63.1 P/Share
|
|
Jan 18
2024
|
Jean Jacques Bienaime Director |
BUY
Small Acquisition
|
Direct |
40
+0.01%
|
$3,680
$92.6 P/Share
|
|
Jan 10
2024
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
10,000
-2.3%
|
$960,000
$96.38 P/Share
|
|
Jan 10
2024
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.25%
|
$630,000
$63.1 P/Share
|
|
Jan 09
2024
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
10,000
-2.3%
|
$980,000
$98.19 P/Share
|
|
Jan 09
2024
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.25%
|
$630,000
$63.1 P/Share
|
|
Jan 08
2024
|
Richard A Meier Director |
SELL
Bona fide gift
|
Direct |
3,000
-2.6%
|
-
|
|
Jan 08
2024
|
Jean Jacques Bienaime Director |
BUY
Small Acquisition
|
Direct |
50
+0.01%
|
$4,950
$99.05 P/Share
|